UNSPSC 51391802: Gepefrine

This classification denotes an alpha-adrenergic agonist with the molecular formula C9H13NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V51RRX51VH, chemically known as phenol, m-(2-aminopropyl)- but generally known as gepefrine, which bears US NIH Compound Identifier 102551. European Medicines Agency schedules Gepefrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07896MIG. World Health Organization schedules gepefrine in its Anatomical Therapeutic Chemical (ATC) Classification.

UNSPSC 51391802 Gepefrine, a Commodity code, does not align with recent state and local procurement activity tagged under it. The code nominally describes a pharmaceutical agent, but the recent opportunities record solicitations for naloxone (an opioid antagonist) and drug deactivation systems, and for pharmacy benefit program structure and direct-to-manufacturer prescription fulfillment — neither of which fall within the scope of a single active pharmaceutical ingredient. The mismatch signals that this code shows little relevant recent activity for firms pursuing contracts to supply gepefrine itself or services built around it. State and local health agencies and human services departments appear to be the issuing bodies when procurement does occur under related pharmaceutical codes, but the current opportunities block does not reflect gepefrine-specific demand.

Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, but this is a naloxone procurement, not a gepefrine solicitation. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to explore direct-to-manufacturer prescription programs, which addresses pharmacy benefit design rather than a specific pharmaceutical purchase. Neither opportunity reflects active market demand for gepefrine under this code. Firms evaluating this Commodity code should treat it as a watch category pending evidence of direct gepefrine solicitations from state health departments, county health systems, or emergency services agencies; current activity does not support pursuit.